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AIMS
To explore if there is a difference between patients and healthcare professionals (HCPs) in time to reporting drug–adverse drug
reaction (ADR) associations that led to drug safety signals.
METHODS
This was a retrospective comparison of time to reporting selected drug–ADR associations which led to drug safety signals between
patients and HCPs. ADR reports were selected from the World Health Organization Global database of individual case safety re-
ports, VigiBase. Reports were selected based on drug–ADR associations of actual drug safety signals. Primary outcome was the
difference in time to reporting between patients and HCPs. The date of the ﬁrst report for each individual signal was used as time
zero. The difference in time between the date of the reports and time zero was calculated. Statistical differences in timing were
analysed on the corresponding survival curves using a Mann–Whitney U test.
RESULTS
In total, 2822 reports were included, of which 52.7% were patient reports, with a median of 25% for all included signals. For all
signals, median time to signal detection was 10.4 years. Overall, HCPs reported earlier than patients: median 7.0 vs. 8.3 years
(P < 0.001).
CONCLUSIONS
Patients contributed a large proportion of reports on drug–ADR pairs that eventually became signals. HCPs reported 1.3 year
earlier than patients. These ﬁndings strengthen the evidence on the value of patient reporting in signal detection and highlight an
opportunity to encourage patients to report suspected ADRs even earlier in the future.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Adverse drug reaction (ADR) reporting by patients has been shown to contribute to the detection of new drug safety
signals.
WHAT THIS STUDY ADDS
• Overall, healthcare professionals (HCPs) reported ADRs that led to drug safety signals slightly earlier than patients.
• A difference in time to reporting between patients and HCPs was found for signals classiﬁed as important as well as
nonimportant medical events.
• A difference in time to reporting between patients and HCPs was present for reports from the USA, which has a long
history of reporting ADRs by patient, but was negligible for reports from Europe, where patients were able to report since
2012, with some countries being earlier.
• Analysis of the individual signals demonstrated that the difference in median time to reporting between patients and
HCPs compared to the total time to signal detection was small for most signals.
Introduction
Pharmacovigilance centres around the world have an impor-
tant role to monitor the safety of drugs in the postmarketing
phase. They collect information about adverse drug reactions
(ADRs) spontaneously reported by healthcare professionals
and patients, for example by the Yellow Card Scheme in the
UK. Having patients directly reporting to the national
pharmacovigilance centres is relatively new in most areas of
the world. In 2012 in the European Union, it became manda-
tory by law for countries to give patients the opportunity to
report possible ADRs directly to the competent authority,
although several countries introduced reporting by patients
earlier [1, 2]. In some countries, such as the USA, patients
have already been able to report for decades. Reports from
patients are a well-established source of information in drug
safety [3]. Despite patient participation gaining more and
more attention worldwide, this does not necessarily mean
that countries have fully embraced patient reporting [4, 5].
More experience and sharing of information between coun-
tries is needed to fully understand its value.
Studies already demonstrated that reports by patients
positively contribute to pharmacovigilance. Patients generally
give an adequate description of the course of clinical symptoms
and they seem more likely to report on the impact of ADRs on
their daily life compared to healthcare professionals [6, 7]. Some
studies found that patients are likely to report more serious
ADRs compared to healthcare professionals, while others dem-
onstrate the opposite [8–12]. There are also studies that demon-
strated no difference in seriousness between both groups [6, 7,
13, 14]. Although there have been concerns about the quality
of patient reports in the past, it has recently been shown that
the clinical quality of information reported by patients is com-
parable to that of healthcare professionals [15]. Concerning
the detection of new drug safety signals, it was demonstrated
that reports by patient are taken into account [16–19]. These sig-
nals include ADRs not listed in the Summary of Product Charac-
teristics (SmPC) and new aspects of knownADRs. A recent study
in the Netherlands exploring signals detected from 2010 to
2015 showed that the number of reports directly from patients
in the signals rose from 16 (10% of total) in 2010 to 161
(28.3% of total) in 2015 [16]. There were 137 serious reports in
all examined signals (30.8% of all patient reports) compared to
224 healthcare professional reports (19.2% of total reports).
Less is known about the difference in timing of reporting
by patients and healthcare professionals. It has been
suggested that reporting by patients contributes to an earlier
detection of drug safety signals [20, 21]. Indeed, a certain
number of reports is necessary to generate new drug safety
signals and reports by patients provide an additional source
of information. In addition, patients may report earlier on
certain ADRs compared to healthcare professionals; for the
latter group one of the reasons for not reporting a possible
ADR to a pharmacovigilance centre may be the uncertainty
that it actually concerns an ADR.
Little is known about the extent to which patient reports
might impact on timely signal detection and whether this is
different for ADRs classiﬁed as so called important medical
events (IMEs), deﬁned as those events that result in death or
require (prolonged) hospitalization, and those not classiﬁed
as IMEs [22, 23]. Furthermore, comparing the USA and
Europe may provide additional insights given the extensive
experience with patient reporting in the USA, vs. Europe
where patient reporting is relatively new. In the USA there
has been a relatively constant ﬂow of patient reports over
time, while in most European countries the number of
patient reports continues to rise [3, 24, 25]. Also, in the USA
patient reports are mostly received through pharmaceutical
companies, while in Europe patients mostly report directly
to the national pharmacovigilance centre [2].
This study aims to explore if there is a difference between
patients and healthcare professionals in time to reporting
drug–ADR associations that led to drug safety signals. The
secondary aims are to explore if there is a difference in time
to reporting between patients and healthcare professionals
for drug safety signals characterized as IMEs, and if there is a
difference for reports from those regions with a long history
of patient reporting (USA) vs. a region with a short history
of patient reporting (Europe).
Method
Study design and data source
This was a retrospective comparison of time to reporting
selected drug–ADR associations that led to drug safety signals
between patients and healthcare professionals.
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ADR reports were selected from the World Health Organi-
zation (WHO) global database of individual case safety
reports, VigiBase. As of June 2017, this database contained
over 15 million ADR reports received from over 120 member
countries of the WHO programme for international drug
monitoring [26].
We selected all reports of drug–ADR associations present
in all drug safety signals detected by the Netherlands
Pharmacovigilance Centre Lareb between 2011 and 2015. At
Lareb, reports by patients were handled in the same way as
those from healthcare professionals and they were fully
integrated into the process of signal detection. During signal
detection, qualitative aspects as well as quantitative aspects
(disproportionality analysis) are taken into account [27, 28].
Signals covered a wide range of different ADRs. We excluded
signals on drug interactions, multiple suspected drugs, and
dosing or administration errors. All signals are publicly
accessible on the Lareb website [29, 30]. In total, 60 signals
were included in this study.
Based on the drug–ADR associations present in the
selected signals, ADR reports were selected from a frozen
VigiBase version as of October 2015. Selection of reports in
VigiBase was based on the WHO drug classiﬁcation system,
the ATC-5 code or the drug’s brand name [31] and the
Medical Dictionary for Regulatory Activities MedDRA
Preferred term coding [32], depending on the drug–ADR
association described in the signal. The drug needed to be
classiﬁed as ‘suspected’ or ‘interacting’ on the reports.
Reports had to be ﬁled in the database before dissemination
of the drug safety signals.
Only reports that had the E2B structure, an international
standard for transmitting ADR reports, were included. Only
reports that were either pure patient reports (E2B reports with
a single reporter whose qualiﬁcation was Consumer or other
non-health professional) or pure healthcare professional
reports (E2B reports with a single reporter whose qualiﬁcation
was Physician, Pharmacist or Other health professional) were
included. There was no exclusion of duplicate reports; in case
the event had been reported by different sources, these were
all take into account.
We only included data from countries if they accepted
reports from patients at the time of the ﬁrst report for the
speciﬁc drug–ADR association in VigiBase. Start date of pa-
tient reporting in the speciﬁc countries was obtained from lit-
erature [2] or through personal contacts with the national
pharmacovigilance centres. This was to ensure that countries
not only formally accepted patient reports but actually did so
in practice. We excluded data from countries with no patient
reports in VigiBase. See Figure 1 for a ﬂowchart of the
Methods of data collection.
Outcomes
The primary outcome was the difference in time to reporting
between patients and healthcare professionals. The second-
ary outcomes were the differences in time to reporting
between patients or healthcare professionals for (i) IMEs vs.
non-IMEs, according to the European Medicines Agency
(EMA)-list of Important Medical Events, according to
MedDRA terminology [18], and (ii) for the USA vs. Europe.
For Europe, we included countries within the European
Figure 1
Flowchart of the methods of data collection. Signals’ exclusion
criteria concerned: drug interactions, multiple suspected drugs,
and dosing or administration errors. ADR, adverse drug reaction;
IME, important medical event
L. Rolfes et al.
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Union, as well as Iceland and Norway because they
participate in EMA regulatory decision making. Although
Switzerland does not participate in EMA regulatory decision
making, this country accepts reports directly from patients
since 2002 and share a similar culture with the rest of
Europe. For this reason, we decided to take Switzerland into
account as well.
Analysis
The date of the ﬁrst report for each individual signal was used
as time zero. All reports on the same drug–ADR association
from time zero until signal detection were included. We
calculated the difference in time between time zero and the
following reports from patients and healthcare professionals
for each signal individually. Subsequently, data for all signals
were pooled. The percentage of reports originating from
patients was calculated and it was determined whether a
healthcare professional or a patient made the ﬁrst report for
each signal.
Kaplan–Meier plots were used to visualize the reporting
over time by patients and healthcare professionals, respec-
tively. Statistical differences in time to reporting between
patients and healthcare professionals were explored on the
corresponding survival curves using Mann–Whitney U tests.
To investigate the secondary outcomes, subanalyses were
made for signals classiﬁed as (non-)IMEs and reports from
the USA and Europe. In addition, time to reporting was
analysed for healthcare professionals in the USA vs. Europe,
and patients in the USA vs. Europe. Statistical signiﬁcance
was based on a P value <0.05. Data were analysed using the
statistical software program SPSS Statistics, version 22.0
(SPSS, Chicago, IL, USA).
There may be a large difference between reporting of
the ﬁrst report and the time to signal detection for the in-
dividual signals. To explore the meaning of the obtained
difference in time to reporting between patients and
healthcare professionals, relative differences deﬁned as the
difference in median time to reporting by patients and
healthcare professionals divided by the total time until
signal detection, were analysed. The difference in median
between both groups was plotted against the total number
of days until signal detection. For calculating the median,
all signals with at least three patients and three healthcare
professional reports were included.
Results
Characteristics of included signals
In total, 60 signals were included (Table 1). The median time
to signal detection, calculated from the date of the ﬁrst
report for each individual signal, was 10.4 years, with an
interquartile range of 7.6–13.6 years. The signals included
a total number of 2822 reports, of which 1488 (52.7%) were
reported by patients and 1334 (47.3%) by healthcare
professionals. The proportion of patient reports in the
individual signals ranged from 0% to 84.4%, with a median
of 25.0%. A total of 13 signals (21.7%) did not contain any
reports from patients. For 12 signals (20.0%), the ﬁrst report
was made by a patient, for 48 (80.0%) by a healthcare
professional.
A total of 18 (30.0%) signals were classiﬁed as IME (Table 1,
signals in italic) [18]. Overall, IMEs included fewer reports
from patients compared to healthcare professionals, range
0–55.1% (median of 7.2%) vs. non-IMEs 0–84.4% (median of
34.0%). The ﬁrst report was made by a patient for four IMEs
(22.2%) and eight non-IMEs (19.0%).
Patient reports were from 24 different countries: Belgium,
Bulgaria, Canada, the Democratic Republic of the Congo,
Croatia, Czech Republic, Denmark, Estonia, France, Germany,
Greece, Hungary, Iceland, Morocco, the Netherlands, Norway,
Peru, Portugal, Slovakia, Sweden, Switzerland, Turkey, UK
and USA. A total of 2124 reports came from the USA
(61.9% patient reports) and 430 from Europe (21.9% patient
reports) and 268 from non-European countries. For reports
from the USA, 26.8% of the healthcare professional
reports were classiﬁed as IMEs and 7.2% of the patient re-
ports. For reports from Europe, 25.4% of the healthcare pro-
fessional reports were classiﬁed as IMEs, and 37.2% of the
patient reports.
Comparison in time to reporting
The overall cumulative distribution of time to reporting of
patients and healthcare professionals is shown in Figure 2.
The corresponding Mann–Whitney U test suggested that
there was a statistically signiﬁcant difference between these
distributions (P < 0.001) Healthcare professionals generally
reported earlier than patients with a median time to
reporting of 7.0 vs. 8.3 years, and corresponding interquar-
tile ranges of respectively 3.9–9.5 and 6.2–10.4 years. For
IMEs, healthcare professionals and patients took a median
time to reporting of 6.9 vs. 8.1 years and for non-IMEs
7.0 vs. 8.2 years (Figure 3a, b). In both cases, there was
an overall statistically signiﬁcant difference in the time
Figure 2
The cumulative distribution of time of adverse drug reaction (ADR)
reports, after the ﬁrst ADR report, coming from patients and
healthcare professionals, Mann–Whitney U P < 0.001
L. Rolfes et al.
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distribution (P < 0.001). The cumulative distributions of re-
ports from the USA and Europe are shown in Figure 4a, b.
For the USA, median time to reporting for healthcare pro-
fessionals and patients was 6.0 vs. 8.1 years and for
Europe 7.8 vs. 7.9 years. The corresponding tests for distri-
bution differences were both signiﬁcant, P < 0.001 and
P = 0.03, respectively. In addition, healthcare professionals
in the USA reported earlier compared to those in Europe
(P < 0.001). For patients, no statistically signiﬁcant differ-
ence was shown (P = 0.531).
Individual signals
The analysis of the individual signals showed that for
seven signals a statistically signiﬁcant difference in time
to reporting between the two groups was present
(Table 1). For two of these signals, patients reported signif-
icantly earlier than healthcare professionals: ‘paroxetine
associated with migraine’ (P = 0.002) and ‘proguanil
hydrochloride/atovaquone associated with psychotic disor-
der’ (P = 0.036).
To explore the meaning of the differences in time to
reporting between patients and healthcare professionals,
the difference in median days between reports by patients
and healthcare professionals divided by the number of
days until signal detection, was plotted against the
number of days until signal detection (see Figure 5). A
positive ratio means earlier reporting by healthcare profes-
sionals and a negative ratio earlier reporting by patients.
The ratio-lines in the ﬁgure give an indication of the
meaning of the difference in median between both
groups. A small ratio in combination with a high number
Figure 3
The cumulative distribution of time of adverse drug reaction (ADR)
reports, after the ﬁrst ADR report, coming from patients and
healthcare for: a) important medical events, Mann–Whitney
U P < 0.001, b) non- important medical events, Mann–Whitney
U P value of <0.001
Figure 4
The cumulative distribution of time of adverse drug reaction (ADR)
reports, after the ﬁrst ADR reports, coming from patients and
healthcare for: a) study cases coming from the USA, Mann–Whitney
U P < 0.001, b) study cases coming from Europe, Mann–Whitney U
P = 0.03
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of days until signal detection indicated little clinical rele-
vance, while a high ratio in combination with a small
number of days until signal detection indicated a higher
level of clinical relevance. In total, 34 signals were in-
cluded in the scatter plot; of those, ﬁve were classiﬁed as
IMEs and 29 as non-IMEs. 19 out of 34 signals had a ratio
between –0.1 and 0.1; three of those signals were classiﬁed
as IMEs and 16 as non-IMEs. For one signal, there was no
difference between patients and healthcare professionals,
for 11 signals, patients reported earlier and for 22
healthcare professionals reported earlier. For patients, there
was one signal with a ratio of less than –0.3. For health-
care professionals, there were three signals with a ratio
over 0.3, including two classiﬁed as IMEs.
Discussion
With the increasing interest in patients as stakeholders in
pharmacovigilance, it is important to explore the impact of
patient reporting on early detection of new drug safety
signals in pharmacovigilance. We demonstrated that ADRs
that led to drug safety signals were generally reported earlier
by healthcare professionals than patients, with an overall
median difference of 1.3 years. This difference was present
for ADRs classiﬁed as IMEs as well as non-IMEs. Although a
difference in timing between both groups was present for
the USA, the difference was negligible for Europe. The ratios
in time to reporting were small, indicating that the difference
in time to reporting ADRs between patients and healthcare
professionals had limited impact on the overall time to signal
detection for most signals.
It has been suggested that patient reports might enable
earlier signal detection [20, 21]. In 1996, Egberts et al. [21]
compared information obtained from patients and
healthcare professionals on the, at the time, new antidepres-
sant paroxetine. At that time in the Netherlands, patients
were not yet able to report directly to the
pharmacovigilance centre but could consult a telephone
medicines information service maintained by pharmacists.
Comparing the timing of reports by healthcare professionals
to the national pharmacovigilance centre with questions by
patients to the telephone service, showed that patients
posted questions to this telephone service earlier as com-
pared to healthcare professionals, with a mean time lag for
all suspected reactions of 229 days. Hammond et al. [33]
explored time to signal detection for four randomly selected
GlaxoSmithKline marketed drugs, for reports of patients and
healthcare professionals combined and as separate groups.
Using disproportionality analysis, 23 signals of disproportion-
ate reporting were identiﬁed, of which 52.2% (12 of 23) at an
earlier stage when the patient reports were included, 34.8%
(eight of 23) in the same year and 13% (three of 23) later
when patient reports were included. The aforementioned
studies focussed on time-aspects of statistical drug–ADR
reporting associations not necessarily representing safety
signals. To our knowledge, including actual drug safety
signals to compare time to reporting between patients and
healthcare professionals has not been explored before.
To ﬁnd a new drug safety signal, a certain number of
reports is necessary. The introduction of direct patient
reporting introduced a growth in the number of reports by
patients. This growth also reﬂects in the amount of patient
reports that contributed to new drug safety signals [16]. In
the current study, we found a relatively high proportion of
patient reports in the included signals; 52.7% of all reports
and a range of 0% to 84.4% for the individual signals. Reports
by patients are more represented in ADRs classiﬁed as non-
IMEs than IMEs; range of 0–84.4% vs. 0–55.1% respectively.
Analysing signals individually, we demonstrated that, for
some, patients were earlier in reporting and, for others,
Figure 5
Scatterplot of the difference in median days between reports by patients and healthcare professionals divided by the number of days until signal
detection, plotted against the number of days until signal detection. Closed bullet = signal classiﬁed as non-IME; open bullet = signal classiﬁed as
IME, The ratio was calculated by the difference in median divided to the number of days until signal detection. A positive ratio means earlier
reporting by healthcare professionals and a negative ratio earlier reporting by patients
L. Rolfes et al.
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healthcare professionals were earlier. It is therefore plausible
that reports by patients can contribute to earlier signal
detection. There are some points to consider concerning the
data used for this study. In our study, >60% of the reports
from the USA originated from patients. This was higher than
in another analysis from the USA, which showed that from
2006 to 2014 an average of 47% of all reports were from pa-
tients [3]. This may be explained by the nature of the selected
signals. It was furthermore striking that the percentage
reports classiﬁed as IME was higher for patient reports from
Europe compared to those coming from the USA. The
percentage of IMEs included in all patient reports was in line
with previous results of a study on Dutch drug safety signals
by van Hunsel et al. [16]. They showed that of all reports by
patients that contributed to a signal in the Netherlands from
2010 to 2015, 30.5% included an ADR classiﬁed as IME. This
was a higher percentage than reports by healthcare profes-
sionals (22.5%) [16].
By selecting reports from the international database
VigiBase, we could include a high number of reports which
allowed us to analyse signals by importance of the event
and by region of origin. It must be kept in mind that data
pooling can inﬂuence the outcome. On average, the median
time to signal detection, calculated from time zero, was
10.4 years. Given the large variation in number of reports
per signal, signals with many reports contributed to a larger
extent to the overall outcome. To place our results in perspec-
tive, we therefore also explored all signals individually.
The reporting rate may vary over time and may differ
between patients and healthcare professionals. It can be
inﬂuenced by factors, such as media attention or discussions
on the internet [34, 35]. As far as we know, there was no
speciﬁc media attention for the drug–ADR associations
included in our study, but differences in timing due to
external factors cannot be ruled out. In addition, for Europe
due to changes in the pharmacovigilance legislation in 2012
it is possible that this legal change caused a steeper growth
in patient reporting compared to healthcare professional
reporting. This may have contributed to the difference in
time to reporting we found between healthcare professional
reports from the USA vs. Europe.
Conclusion
Patients contributed a large proportion of reports on drug–ADR
pairs that eventually became drug safety signals; 53% overall,
with a median of 25%. This corroborates earlier ﬁndings on
the contribution of patient reports to signal detection in
pharmacovigilance. For all signals, median time to signal detec-
tion was 10.4 years. Healthcare professionals generally reported
1.3 years earlier than patients. This was the case for ADRs
classiﬁed as IMEs as well as non-IMEs. This highlights an oppor-
tunity to further increase the value of patient reporting in the
future, by encouraging patients to report suspected ADRs earlier.
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